Third Party Agreements - Additional Information (Details) - USD ($) $ in Millions |
3 Months Ended | 12 Months Ended | |
|---|---|---|---|
Jan. 28, 2022 |
Mar. 31, 2026 |
Dec. 31, 2022 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Research and development in process 1 | $ 1.1 | ||
| License agreement termination description | twelve (12) years | ||
| Regeneron Pharmaceuticals, Inc. | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Revenue recognized | $ 5.0 | ||
| Exercise Fee Paid | $ 20.0 | 20.0 | |
| Licence agreement additional revenue recognised | $ 25.0 | ||
| Non refundable upfront payment received | $ 25.0 | ||
| Additional payment for research funding received | 20.0 | ||
| Licence agreement additional amount payable of option exercise fees | $ 80.0 |